AR053575A1 - COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY - Google Patents
COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPYInfo
- Publication number
- AR053575A1 AR053575A1 ARP060101410A ARP060101410A AR053575A1 AR 053575 A1 AR053575 A1 AR 053575A1 AR P060101410 A ARP060101410 A AR P060101410A AR P060101410 A ARP060101410 A AR P060101410A AR 053575 A1 AR053575 A1 AR 053575A1
- Authority
- AR
- Argentina
- Prior art keywords
- controlled release
- release formulation
- combination
- inhibitor
- benign hyperplasia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un procedimiento novedoso para el tratamiento de síntomas en hiperplasia benigna de prostata. A este respecto se usan de forma simultánea: (1) un antagonista del adrenoreceptor alfa-1 en formulacion de liberacion controlada o un inhibidor de 5-alfa- reductasa y (2) un inhibidor de PDE 5 de GMPc en formulacion de liberacion controlada o un inhibidor de PDE 5 de GMPc con mayor tiempo de semivida. Reivindicacion 2: Forma farmacéutica segun la reivindicacion 1, que contiene una formulacion de liberacion controlada de tamsulosina, alfuzosina, doxazosina o terazosina así como una formulacion de liberacion controlada de vardenafilo o sildenafilo. Reivindicacion 3: Forma farmacéutica segun la reivindicacion 1, que contiene una formulacion de liberacion controlada de tamsulosina, alfuzosina, doxazosina o terazosina así como tadalafilo.A novel procedure for the treatment of symptoms in benign prostatic hyperplasia. In this regard, the following are used simultaneously: (1) an alpha-1 adrenoceptor antagonist in a controlled release formulation or a 5-alpha reductase inhibitor and (2) a cGMP PDE 5 inhibitor in a controlled release formulation or a cGMP 5 PDE inhibitor with longer half-life. Claim 2: Pharmaceutical form according to claim 1, containing a controlled release formulation of tamsulosin, alfuzosin, doxazosin or terazosin as well as a controlled release formulation of vardenafil or sildenafil. Claim 3: Pharmaceutical form according to claim 1, containing a controlled release formulation of tamsulosin, alfuzosin, doxazosin or terazosin as well as tadalafil.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005016981A DE102005016981A1 (en) | 2005-04-13 | 2005-04-13 | Combination therapy for benign prostatic hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053575A1 true AR053575A1 (en) | 2007-05-09 |
Family
ID=36608700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101410A AR053575A1 (en) | 2005-04-13 | 2006-04-11 | COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1888075A1 (en) |
JP (1) | JP2008535877A (en) |
KR (1) | KR20080007252A (en) |
CN (1) | CN101193638A (en) |
AR (1) | AR053575A1 (en) |
AU (1) | AU2006233567A1 (en) |
BR (1) | BRPI0610634A2 (en) |
CA (1) | CA2605224A1 (en) |
CR (1) | CR9427A (en) |
DE (1) | DE102005016981A1 (en) |
DO (1) | DOP2006000074A (en) |
GT (1) | GT200600145A (en) |
IL (1) | IL186604A0 (en) |
MA (1) | MA29683B1 (en) |
MX (1) | MX2007012567A (en) |
PE (1) | PE20061338A1 (en) |
RU (1) | RU2007141518A (en) |
SV (1) | SV2008002477A (en) |
TN (1) | TNSN07385A1 (en) |
TW (1) | TW200716122A (en) |
UY (1) | UY29473A1 (en) |
WO (1) | WO2006108519A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
CA2633570A1 (en) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
EP1875914A1 (en) * | 2006-07-07 | 2008-01-09 | Teva Pharmaceutical Industries Ltd. | Solid compositions comprising tadalafil and at least one carrier |
DE102007028869A1 (en) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | A process for the preparation of a medicament containing tadalafil |
AU2008334932B2 (en) | 2007-12-13 | 2014-05-22 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
CA2709104C (en) | 2007-12-13 | 2017-06-13 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
US8885621B2 (en) | 2010-04-26 | 2014-11-11 | Intel Corporation | Method, apparatus and system for switching traffic streams among multiple bands |
WO2013123965A1 (en) * | 2012-02-20 | 2013-08-29 | Synthon Bv | A fixed dose pharmaceutical formulation |
CN102727456B (en) * | 2012-07-03 | 2016-06-22 | 北京科信必成医药科技发展有限公司 | Drug port cavity disintegrating tablet and preparation method thereof |
AU2014299447B2 (en) * | 2013-06-28 | 2019-01-17 | Hanmi Pharm. Co., Ltd. | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin |
CA2919198A1 (en) | 2013-07-23 | 2015-01-29 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist |
KR20150056443A (en) * | 2013-11-15 | 2015-05-26 | 한미약품 주식회사 | Composite formulation comprising tadalafil and amlodipine |
EP3150201B1 (en) * | 2014-06-30 | 2020-02-19 | Hanmi Pharm. Co., Ltd. | Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation |
WO2016003181A1 (en) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | Composite preparation comprising active ingredient-containing film coating layer |
WO2016003180A1 (en) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | Composite preparation comprising 5-α-reductase inhibitor-containing film coating layer, and method for producing the composite preparation |
KR20240010751A (en) * | 2014-11-20 | 2024-01-24 | 세레니티 파마슈티컬즈 엘엘씨 | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
WO2017171508A1 (en) * | 2016-03-31 | 2017-10-05 | 한미약품 주식회사 | Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate |
KR101835506B1 (en) * | 2016-10-25 | 2018-03-07 | 주식회사 에스텍파마 | Rapid-acting mixture of tablet containing dutasteride and tadalafil |
CN108066347B (en) * | 2016-11-16 | 2021-02-02 | 深圳万和制药有限公司 | Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride |
KR101879133B1 (en) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | Agents for preventing or treating urinary disease and preparing the same |
TR201715231A2 (en) * | 2017-10-09 | 2019-04-22 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
-
2005
- 2005-04-13 DE DE102005016981A patent/DE102005016981A1/en not_active Withdrawn
-
2006
- 2006-03-29 DO DO2006000074A patent/DOP2006000074A/en unknown
- 2006-03-31 CN CNA2006800207814A patent/CN101193638A/en active Pending
- 2006-03-31 AU AU2006233567A patent/AU2006233567A1/en not_active Abandoned
- 2006-03-31 WO PCT/EP2006/002941 patent/WO2006108519A1/en active Application Filing
- 2006-03-31 JP JP2008505765A patent/JP2008535877A/en active Pending
- 2006-03-31 MX MX2007012567A patent/MX2007012567A/en not_active Application Discontinuation
- 2006-03-31 RU RU2007141518/15A patent/RU2007141518A/en unknown
- 2006-03-31 BR BRPI0610634-0A patent/BRPI0610634A2/en not_active Application Discontinuation
- 2006-03-31 KR KR1020077026260A patent/KR20080007252A/en not_active Application Discontinuation
- 2006-03-31 CA CA002605224A patent/CA2605224A1/en not_active Abandoned
- 2006-03-31 EP EP06723901A patent/EP1888075A1/en not_active Withdrawn
- 2006-04-07 SV SV2006002477A patent/SV2008002477A/en not_active Application Discontinuation
- 2006-04-10 GT GT200600145A patent/GT200600145A/en unknown
- 2006-04-11 AR ARP060101410A patent/AR053575A1/en unknown
- 2006-04-11 PE PE2006000383A patent/PE20061338A1/en not_active Application Discontinuation
- 2006-04-12 TW TW095112920A patent/TW200716122A/en unknown
- 2006-04-12 UY UY29473A patent/UY29473A1/en not_active Application Discontinuation
-
2007
- 2007-10-09 CR CR9427A patent/CR9427A/en not_active Application Discontinuation
- 2007-10-11 IL IL186604A patent/IL186604A0/en unknown
- 2007-10-11 TN TNP2007000385A patent/TNSN07385A1/en unknown
- 2007-10-29 MA MA30335A patent/MA29683B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2006000074A (en) | 2006-10-15 |
CA2605224A1 (en) | 2006-10-19 |
TW200716122A (en) | 2007-05-01 |
BRPI0610634A2 (en) | 2010-07-13 |
EP1888075A1 (en) | 2008-02-20 |
WO2006108519A1 (en) | 2006-10-19 |
PE20061338A1 (en) | 2007-01-28 |
UY29473A1 (en) | 2006-11-30 |
MA29683B1 (en) | 2008-08-01 |
AU2006233567A1 (en) | 2006-10-19 |
RU2007141518A (en) | 2009-05-20 |
GT200600145A (en) | 2007-04-10 |
SV2008002477A (en) | 2008-02-08 |
IL186604A0 (en) | 2008-01-20 |
TNSN07385A1 (en) | 2009-03-17 |
MX2007012567A (en) | 2007-12-10 |
DE102005016981A1 (en) | 2006-10-19 |
JP2008535877A (en) | 2008-09-04 |
CR9427A (en) | 2007-12-17 |
KR20080007252A (en) | 2008-01-17 |
CN101193638A (en) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053575A1 (en) | COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY | |
DOP2022000096A (en) | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | |
ECSP109934A (en) | COMPOUND - 946 | |
AR048819A1 (en) | SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
NI201000004A (en) | TRISUSTITUED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES. | |
WO2015193740A3 (en) | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor | |
CO6612228A2 (en) | Jak2 inhibitors and their use in the treatment of myeloproliferative diseases and cancer | |
CL2008001743A1 (en) | Use of a compound derived from quinazoline to treat cancer; use of the compound and another antineoplastic compound; quinazoline derived compounds; and pharmaceutical composition comprising them. | |
CL2008001364A1 (en) | Use of compounds derived from imidazol (1,2-b) pyridazine and pyrazolo (1,5-a) pyrimidine tyrosine kinase inhibitors pi-to treat benign or malignant tumor, among others; imidazole (1,2-b) pyridazine and pyrazolo (1,5-a) pyrimidine compounds; pharmaceutical compositions; and method of preparing compounds. | |
PE20151070A1 (en) | TYROSINE INHIBITORS - BRUTON KINASE | |
CR11499A (en) | COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS | |
NO20071078L (en) | Antiviral compounds | |
NO20070866L (en) | Antiviral compounds. | |
CL2011000710A1 (en) | Pharmaceutical combination comprising a specific smoothened inhibitor and a specific pi3 kinase inhibitor; and use in the treatment of cancer. | |
CL2011000489A1 (en) | Compounds derived from pyrimido [5,4-d] pyrimidine, which act as tyrosine kinase inhibitors; and pharmaceutical compositions that comprise them, useful in the treatment of diseases characterized by excessive or abnormal cell proliferation | |
MX2019003134A (en) | Combination therapy. | |
CR20130459A (en) | DERIVATIVES OF PIRIDINIL- AND PIRAZINIL-METILOXI-ARIL USEFUL AS INHIBITORS OF TIROSINA CINASA DEL BAZO (Syk) | |
CL2007003251A1 (en) | Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer. | |
CL2014000606A1 (en) | Pharmaceutical combination comprising the compound 2- {2 - [(2s) -2-methyl-2,3-dihydro-1h-indol-1-yl] -2-oxoethyl} -6- (morpholin-4-yl) pyrimidin -4- (3h) -one and at least one inhibitor of the mapk pathway; pharmaceutical composition; pharmaceutical kit; its use in the treatment of cancer. | |
PA8578001A1 (en) | THERAPEUTIC COMBINATIONS OF ERB B QUINASA INHIBITORS AND ANTINEOPLASIC THERAPIES | |
PE20170469A1 (en) | METHODS TO IMPROVE MYOCARDIAL PERFORMANCE IN PATIENTS WITH PHONTANE SURGERY USING UDENAFILO COMPOSITIONS | |
AR085399A1 (en) | ANTITUMORAL COMBINATION INCLUDING CABAZITAXEL AND CISPLATINO | |
PE20220250A1 (en) | USE OF DOCETAXEL IN THE TREATMENT OF CANCER THROUGH CONTROL OF MAXIMUM LEVELS IN PLASMA | |
CL2021001830A1 (en) | lta4h inhibitors for the treatment of hidradenitis suppurativa | |
AR065918A1 (en) | PHARMACEUTICAL SYNERGIC COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN ENZINE 5 ALFA-REDUCTASE INHIBITOR AND AN ANTAGONIST OF 1-ADRENERGIC RECEIVERS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |